18 de septiembre de 2014 / 8:59 / hace 3 años

Merck KGaA seeks immuno-oncology research partner

FRANKFURT, Sept 18 (Reuters) - German drugs and chemicals maker Merck KGaA is in advanced talks with potential partners for its cancer immunotherapy drug candidate anti-PD-L1, it said on Thursday.

“We are currently in advanced discussions with major oncology players and aim to reach an agreement by year-end,” it said in a statement.

Merck added that it planned to invest an additional 130 to 150 million euros ($168 to $192 million) in its biosimilars unit next year, on top of 100 million euros this year, depending on the outcome of ongoing Phase I studies.

It said it would expand existing partnerships with India’s Dr Reddy’s and Brazil’s Bionovis with another, as yet undisclosed in-licensing agreement for a late-stage biosimilar, initially for smaller emerging markets.

1 US dollar = 0.7759 euro Reporting by Georgina Prodhan; Editing by Ludwig Burger

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below